Headquarters
Switzerland
Every company in the roster headquartered in Switzerland.
Research
Compare company financial metrics
Research adds sourced market cap, cash, runway and annualized R&D figures with metric-specific sorting.
Views
11 of 11 companies
| Company | Pipeline | Most advanced | Next readout |
|---|---|---|---|
 NovartisNVS · NYSE | 57 assets: 29 approved, 9 Ph 3, 10 Ph 2, 9 Ph 1 | indacaterol maleate / mometasone furoatePhase 3 · AsthmaReliable signal | 5 Oct 2026Capmatinib · Phase 1 |
 RocheRHHBY · OTC | 49 assets: 21 approved, 14 Ph 3, 9 Ph 2, 5 Ph 1 | astegolimabPhase 3 · Chronic Obstructive Pulmonary DiseaseReliable signal | 8 Oct 2026RO7247669 · Phase 2 |
 AC ImmuneACIU · Nasdaq | 4 assets: 4 Ph 2 | AFFITOPE PD01A / ACI-7104.056Phase 2 · Parkinson's Disease | 22 Dec 2026JNJ-64042056 · Phase 2 |
 Vifor PharmaPrivate | 4 assets: 3 approved, 1 Ph 3 | PatiromerPhase 3 · Heart FailurePartial signal | 15 Aug 2029Difelikefalin · Phase 2 |
 Alentis Therapeutics AGPrivate | 2 assets: 2 Ph 2 | ALE.P02Phase 1/2 · Non-Small Cell Lung Cancer | 15 Feb 2028ALE.P02 · Phase 1/2 |
 iOncturaPrivate | 2 assets: 2 Ph 2 | IOA-244Phase 1/2 · Non-Small Cell Lung Cancer | Jan 2027IOA-244 · Phase 1/2 |
 Corteria PharmaceuticalsPrivate | 1 asset: 1 Ph 2 | Corteria COR-1167Phase 2 · Heart Failure | None on record |
 Idorsia PharmaceuticalsIDIA · SIX | 1 asset: 1 approved | Approved assets only | None on record |
| 1 asset: 1 Ph 1 | NI-1801Phase 1 · Non-Small Cell Lung Cancer | None on record | |
 MoonLake ImmunotherapeuticsMLTX · Nasdaq | 1 asset: 1 Ph 3 | sonelokimabPhase 3 · Psoriatic ArthritisReliable signal | 15 Jan 2027sonelokimab · Phase 3 |
 SQ InnovationPrivate | 1 asset: 1 approved | Approved assets only | None on record |
Next readout: the earliest estimated primary completion of a trial the company or a partner on the asset runs (ClinicalTrials.gov).